Top Markets
#1 Akedo Akedo +60.74%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.99%
#4 Velvet Velvet +41.65%
#5 Black Phoenix Black Phoenix +34.54%
#6 τemplar τemplar +26.67%
#7 Ribbita by Virtuals Ribbita by Virtuals +18.82%
#8 Bitway Bitway +17.84%
#9 Cap Cap +17.11%
#10 Perle Perle +15.44%
Coin of the day
Akedo Akedo
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Clasificación en acciones #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Precio por acción
$0.41
Última sincronización: 2025-01-23
Capitalización bursátil
$1.08M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio CohBar, Inc. (CWBR)

Categoría

Healthcare
Ingresos de CohBar, Inc. (CWBR)
Ingresos en Jun 2023 TTM: 0.00
Según los últimos informes financieros de CohBar, Inc., los ingresos actuales de la empresa (TTM) son 0.00. En 2021, la empresa obtuvo unos ingresos de 0.00 igual a los ingresos del año 2020, que fueron de 0.00. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de CohBar, Inc. desde 2012 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE